Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs. Glycosylation affects proteins and lipids' structure and functions. Tumours are characterized by aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response.

Methods

We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries. Samples were collected before and during ICI treatment.

Results

We observe th

SUBMITTER: Visconti A 

PROVIDER: S-EPMC9938582 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature